1. US FDA (2006) Guidance for industry. Investigating out-of-specification (OOS) test results for pharmaceutical production
2. Kuwahara S (2007) BioPharm Int 20(11):42–52
3. Summary of Judge Wolin’s Interpretation of GMP Issues Contained in the Court’s Ruling in USA vs Barr Laboratories. GMP Institute, USA (1993) http://www.gmp1st.com/barrsum.htm
4. Hoinowski AM, Motola S, Davis RJ, McArdle JV (2002) Pharm Technol 26(11):40–50
5. Köppel H, Schneider B, Wätzig H (2007) J Pharm Biomed Anal 44:718–729